Vertex Pharmaceuticals Q2 FY26: where the revenue came from and where it went
The whole income statement of Vertex Pharmaceuticals for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2026
- Reported
- Aug 4, 2026
Revenue$3.33B
+12% year over year
Gross profit$2.85B
85% margin
Operating profit$1.25B
37% margin
Net profit$1.10B
33% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 3.33 | 100% | +12% |
| Trikafta/Kaftrio | 2.50 | 75% | −2% |
| Alyftrek | 0.57 | 17% | +266% |
| Manufactured product other | 0.14 | 4% | |
| Casgevy | 0.08 | 2% | |
| Journavx | 0.05 | 2% | |
| Cost of revenue | −0.49 | 15% | |
| Gross profit | 2.85 | 85% margin | −1pp |
| SG&A | −0.58 | 17% | +3pp |
| Other | −1.02 | 31% | |
| Operating profit | 1.25 | 37% margin | −1pp |
| Other income, net | 0.15 | ||
| Tax | −0.29 | ||
| Net profit | 1.10 | 33% margin | −2pp |
175 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest